# Sexual dimorphism: increased sterol excretion leads to hypocholesterolaemia in female hyperbilirubinaemic Gunn rats

Josif Vidimce<sup>1</sup>, Johara Pillay<sup>1</sup>, Onne Ronda<sup>2</sup>, Ai-Ching Boon<sup>1</sup>, Evan Pennell<sup>1</sup>, Kevin J. Ashton<sup>3</sup>, Theo H. van Dijk<sup>4</sup>, Karl-Heinz Wagner<sup>5</sup>, Henkjan J. Verkade<sup>2</sup> and Andrew C. Bulmer<sup>1</sup>

<sup>1</sup>School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia

<sup>2</sup>Pediatric Gastroenterology/Hepatology, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

<sup>3</sup>Faculty of Health Science and Medicine, Bond University, Gold Coast, Australia

<sup>4</sup>Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

<sup>5</sup>Department of Nutritional Sciences and Research Platform Active Ageing, University of Vienna, Vienna, Austria

Edited by: Kim Barrett & Kyle McCommis

The peer review history is available in the supporting information section of this article (https://doi.org/10.1113/JP282395#support-information-section).



#### K-H. Wagner and H. J. Verkade contributed equally to this work.

© 2022 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.

DOI: 10.1113/JP282395

The Journal of Physiology

Abstract Circulating bilirubin is associated with reduced serum cholesterol concentrations in humans and in hyperbilirubinaemic Gunn rats. However, mechanisms contributing to hypocholesterolaemia remain unknown. Therefore, this study aimed to investigate cholesterol synthesis, transport and excretion in mutant Gunn rats. Adult Gunn and control rats were assessed for daily faecal sterol excretion using metabolic cages, and water was supplemented with [1-13C]-acetate to determine cholesterol synthesis. Bile was collected to measure biliary lipid secretion. Serum and liver were collected for biochemical analysis and for gene/protein expression using RT-qPCR and western blot, respectively. Additionally, serum was collected and analysed from juvenile rats. A significant interaction of sex, age and phenotype on circulating lipids was found with adult female Gunn rats reporting significantly lower cholesterol and phospholipids. Female Gunn rats also demonstrated elevated cholesterol synthesis, greater biliary lipid secretion and increased total faecal cholesterol and bile acid excretion. Furthermore, they possessed increased hepatic low-density lipoprotein (LDL) receptor and SREBP2 expression. In contrast, there were no changes to sterol metabolism in adult male Gunn rats. This is the first study to demonstrate elevated faecal sterol excretion in female hyperbilirubinaemic Gunn rats. Increased sterol excretion creates a negative intestinal sterol balance that is compensated for by increased cholesterol synthesis and LDL receptor expression. Therefore, reduced circulating cholesterol is potentially caused by increased hepatic uptake via the LDL receptor. Future studies are required to further evaluate the sexual dimorphism of this response and whether similar findings occur in females with benign unconjugated hyperbilirubinaemia (Gilbert's syndrome).

(Received 20 September 2021; accepted after revision 2 February 2022; first published online 14 February 2022) **Corresponding author** A. C. Bulmer: School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia. Email: a.bulmer@griffith.edu.au

**Abstract figure legend** Female Gunn rats have an unconjugated hyperbilirubinaemia because of dysfunctional UGT1A1 enzyme function. Through an unknown mechanism, UGT1A1 dysfunction and/or elevated unconjugated bilirubin concentrations lead to increased faecal sterol excretion. Increased sterol outflow is potentially compensated by increased SREBP2-mediated cholesterol synthesis and LDL receptor expression, ultimately contributing to reduced circulating cholesterol concentrations.

### Key points

- Female adult hyperbilirubinaemic (Gunn) rats demonstrated lower circulating cholesterol, corroborating human studies that report a negative association between bilirubin and cholesterol concentrations.
- Furthermore, female Gunn rats had elevated sterol excretion creating a negative intestinal sterol balance that was compensated for by elevated cholesterol synthesis and increased hepatic low-density lipoprotein (LDL) receptor expression.
- Therefore, elevated LDL receptor expression potentially leads to reduced circulating cholesterol levels in female Gunn rats providing an explanation for the hypocholesterolaemia observed in humans with elevated bilirubin levels.
- This study also reports a novel interaction of sex with the hyperbilirubinaemic phenotype on sterol metabolism because changes were only reported in females and not in male Gunn rats.
- Future studies are required to further evaluate the sexual dimorphism of this response and whether similar findings occur in females with benign unconjugated hyperbilirubinaemia (Gilbert's syndrome).

### Introduction

Cardiovascular diseases (CVDs) cause the greatest number of deaths globally, with atherosclerosis being an important contributor. The development of atherosclerosis is dependent on the complex interplay between rising plasma cholesterol concentrations and systemic inflammation. Thus, elevated cholesterol concentrations are a critical risk factor for CVD mortality (Tabas *et al.* 2015). Despite the effectiveness of statins to reduce plasma cholesterol concentrations, they only reduce the clinical manifestations of atherosclerosis by 20–40% and carry an important side effect profile limiting their long-term use in some patient groups (Insull, 2009). Therefore, there is an important need for more effective medication to prevent and treat CVDs.

Although formerly considered a toxic breakdown product of haem catabolism, growing evidence supports a protective role for unconjugated bilirubin (UCB) against CVDs (Horsfall et al. 2013; Bulmer et al. 2018). Furthermore, individuals with Gilbert's syndrome (GS) who possess mildly elevated plasma UCB concentrations due to impaired UGT1A1 function are protected from coronary artery disease, ischaemic heart disease, atherosclerosis and all-cause mortality (Hopkins et al. 1996; Novotný & Vítek, 2003; Lin et al. 2006; Horsfall et al. 2013). Initially, UCB was demonstrated to possess potent antioxidant activity against peroxyl radicals and against low-density lipoprotein (LDL) oxidation, providing one potential mechanism to explain CVD protection (Stocker et al. 1987; Neuzil & Stocker, 1994; Bulmer et al. 2008; Horsfall et al. 2013), although additional mechanisms likely contribute (Bulmer et al. 2018).

Interestingly, an observational study reported that GS individuals demonstrate reduced serum concentrations of oxidized LDL (oxLDL) *and* total LDL cholesterol (LDL-C) (Boon *et al.* 2012). Therefore, it is unclear whether the antioxidant properties of UCB reduce the formation of oxLDL or whether reduced oxLDL concentrations are secondary to the overall reduction in LDL-C found with increasing plasma UCB concentrations. Recent epidemiological studies report that UCB is associated

with lower total cholesterol and LDL-C, indicating that UCB potentially also regulates cholesterol metabolism in addition to functioning as an antioxidant (Bulmer et al. 2013; Seyed Khoei et al. 2018). In agreement, female hyperbilirubinaemic (Gunn) rats also report >50% lower serum cholesterol concentrations than normobilirubinaemic controls. However, in contrast to human studies, the hypocholesterolaemic effects appear to be sex-specific in rats with a smaller reduction observed in male Gunn rats (Wallner et al. 2013). Similarly, we have observed profound sexual dimorphism in body composition, mitochondrial function and fat metabolism in hyperbilirubinaemic Gunn rats, the reason for which remains unknown (Vidimce et al. 2021). However, these studies suggest that UCB and/or UGT1A1 impairment may reduce circulating cholesterol concentrations, distinct from UCB's antioxidant properties (Bulmer et al. 2013).

Recent studies demonstrate that UCB is a peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ) agonist, similar in potency to fenofibrate (Stec et al. 2016). Additionally, UCB is an atypical agonist of the Aryl hydrocarbon receptor (AhR) (Phelan et al. 1998). PPAR $\alpha$  and AhR are ligand-activated transcription factors that regulate genes involved in lipid metabolism, and their activation may affect circulating cholesterol and triglyceride concentrations (Yoon, 2009; Tanos et al. 2012). The capacity of UCB to activate these receptors may help to explain the hypocholesterolaemic phenotype observed in GS and hyperbilirubinaemic animals; however, the role of these pathways in hyperbilirubinaemia remains poorly understood (Bulmer et al. 2013). Taken together, there is mounting evidence that UCB and/or UGT1A1 impairment can reduce serum cholesterol concentrations. However, nothing is known about whether these effects are mediated by decreased de novo synthesis or increased cholesterol clearance (Bulmer et al. 2013). Therefore, the aim of this study was to determine which aspects of sterol metabolism including synthesis, clearance and hepatic transport, lead to hypocholesterolaemia in Gunn rats and to evaluate whether these effects are sex-dependent.

Josif Vidimce recently completed his PhD at the School of Medical Sciences at Griffith University, Australia, and is now studying clinical medicine, hoping to become a clinical researcher in the future. His current research focuses on the impact of bilirubin on metabolism and whether mild increases in this endogenous molecule can protect against metabolic diseases. Josif's research interests also expand into mitochondrial physiology and lipid metabolism. He has published 10 peer-reviewed journal articles and has presented his research at various national and international conferences.



Table 1. Schematic detailing the timing of various procedures and assessed parameters

Procedures	-1	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
Body weight (all groups)	1	1	1		↑		↑		1		↑		↑		↑		↑		↑		1
Metabolic cage (food intake, faeces/urine collection)	↑											↑				↑				↑	
Blood samples (above)/blood spots (below)		↑							1								Ť	$\uparrow\uparrow$	$\uparrow\uparrow$	$\uparrow\uparrow$	¢
Vehicle I.P. injections			$\uparrow$		$\uparrow$		$\uparrow$		$\uparrow$		↑		$\uparrow$		$\uparrow$		$\uparrow$		↑		↑
H <sub>2</sub> O oral gavage [ <sup>13</sup> C]-acetate Terminal procedures and bile duct cannulation			1	1	¢	1	Ţ	Ţ	Ţ	Ţ	1	Ţ	1	Ţ	Ţ	¢	Ť	↑ ↑	↑ ↑	↑ ↑	$\uparrow \\ \uparrow \\ \uparrow$

Note: arrow ( $\uparrow$ ) indicates on which day a selected procedure is performed. Double arrow ( $\uparrow\uparrow$ ) indicates that the procedure was performed twice (12 h apart).

### Methods

### **Ethics** approval

All procedures were approved by the Griffith University Animal Ethics Research Committee (MSC/02/17/AEC) prior to experimentation. All experiments were carried out according to the Griffith University animal welfare policy and to the principles and regulations as described in the Editorial by Grundy (Grundy, 2015).

### **Chemicals and reagents**

All chemicals and reagents were purchased from Sigma Aldrich (Australia) unless otherwise stated.

### Animals

Breeding pairs of heterozygote Gunn rats on a Wistar background were imported from the Rat Research and Resource Centre (Columbia, MO, USA) and cross-bred to produce both homozygote (hyperbilirubinaemic) and heterozygote (normobilirubinaemic) Gunn rats. Gunn rats were determined phenotypically to be homozygote based on the presence of jaundice in the days after birth and were ear-tagged. The hyperbilirubinaemic phenotype was then confirmed by measuring serum bilirubin concentrations. This Gunn colony is regularly backcrossed with female wild-type Wistar rats, supplied by the Animal Resources Centre (Canning Vale, WA, Australia). From this point, animals expressing hyperbilirubinaemia are referred to as 'Gunn' rats while littermates with normal bilirubin levels are indicated as 'controls'. Rats were housed in an approved animal house facility at Griffith University, Gold Coast, at constant temperature (20°C) and humidity (60%), with a 12 h light:dark cycle. All animals were provided a standard rodent diet (18% protein, 6.2% fat, cholesterol-free; TEKLAD Standard Global, USA) and water *ad libitum*.

### **Experimental protocol**

Adult rats. Thirty six age-matched adult rats ( $\sim 10$  weeks old) were separated into four groups based on sex and phenotype (control female (n = 9), Gunn female (n = 10), control male (n = 8) and Gunn male (n = 9)). Rats were gradually acclimatized to metabolic cages for 2, 5 and then 24 h before entering a 21-day protocol (days -1 to 19; Table 1). On days -1, 10, 14 and 18, animals were housed individually in metabolic cages for a period of 24 h at a time. Food and water were freely available and were weighed before and after each animal was housed in metabolic cages. Additionally, urine and faeces were collected, weighed and stored after each metabolic cage day, and the averaged values of the four individual metabolic cage days was used to report daily food and water consumption, and faecal and urine outputs. Faeces were air-dried for at least 48 h prior to weighing. Body weight was recorded every 2 days for the duration of the study and fasted (6-7 h) blood samples (approx. 1 ml) were collected at day 0 and day 7 via tail bleed (see Blood collection). During the final four days of the study, drinking water was supplemented with [1-13C]-acetate (2% w/v) and blood spots (from the tail) were collected twice daily from non-fasted animals (see Blood collection) to determine *in vivo* cholesterol synthesis. On the final day of the study, animals underwent terminal day procedures (see Bile duct cannulation and terminal procedures) and

were euthanized via surgical removal of the heart under anaesthesia. To control for interventions within future studies, animals were administered 400  $\mu$ l of drinking water daily via oral gavage and 800  $\mu$ l of sterile phosphate buffered saline (Gibco, United Kingdom) every 2 days via intraperitoneal injection (I.P.) for the duration of the study.

**Juvenile rats.** Juvenile rats (3–4 weeks of age) were separated based on sex and phenotype (control females (n = 5), Gunn females (n = 7), control males (n = 8), Gunn males (n = 10)). All animals were fasted for 6 h prior to tissue collection and were anaesthetized using 50 mg kg<sup>-1</sup> sodium pentobarbitone (Lethabarb, Australia) via an I.P. injection. Pedal reflexes were checked to ensure the animals were non-responsive to pain. Blood was then collected via the inferior vena cava and animals were euthanized by surgical removal of the heart. Blood was centrifuged (2000 g, 10 min, 21°C) and the serum was flash-frozen in liquid N<sub>2</sub> and stored at -80°C for later analysis.

### **Blood collection**

Animals were anaesthetized using 2–5% isofluorane (Lyppard, Australia) in 100% oxygen via inhalation (1–2 l min<sup>-1</sup>). Pedal reflexes were routinely checked, and the tip of the tail (1–2 mm) was removed using a sterile scalpel blade to draw blood. The first drop of blood was discarded before collecting ~1 ml of blood in a 1.5 ml microtube (Sarstedt, Australia) or a ~20  $\mu$ l blood spot (~6 mm in diameter) on a filter paper (Sartorius, France). Blood was flash-frozen and stored at -80°C for later analysis. Blood spots were left to air-dry for at least 24 h prior to storage at room temperature (RT).

### Bile duct cannulation and terminal procedures

On day 19 of the protocol, rats were anaesthetized using a ketamine (50 mg kg<sup>-1</sup>) and xylazine (3 mg kg<sup>-1</sup>) mixture via I.P. injection and additional anaesthetic was administered as necessary to maintain a surgical plane. Pedal reflexes were routinely checked prior to and during the procedure. Body temperature was maintained using a heating pad and the temperature was monitored with a rectal probe. A midline laparotomy allowed access to and identification of the common bile duct, with the aid of a dissecting microscope. The bile duct was cannulated with 0.78 o.d.  $\times$  0.32 i.d. mm tubing (Microtube Extrusions, Australia) and secured in place with a drop of superglue and sutures. Once the bile duct was secured, the abdomen was closed and secured with sutures to maintain body temperature. Bile was collected for 35 min, with the first 5 min discarded while the rest was collected into pre-weighed 1.5 ml microtubes on ice. During the procedure, bile was protected from light by covering the collection tube with foil. Immediately after bile collection, the tubes were weighed, flash-frozen in liquid N2 and stored at -80°C. Bile flow was determined gravimetrically assuming a density of 1 g ml<sup>-1</sup>. Rates of lipid secretion were calculated using bile flow and biliary lipid concentrations. After surgery, blood was collected from the inferior vena cava and centrifuged (2000 g, 10 min, 4°C). The supernatant was flash-frozen in liquid N<sub>2</sub> and stored at -80°C. Next, the rats were euthanized by surgical removal of the heart. Liver tissue was rinsed with cold dPBS (Gibco, United Kingdom) and one section was flash-frozen with liquid N<sub>2</sub> and stored at -80°C while the other was stored in RNAlater solution (Invitrogen, Australia) at 4°C for at least 24 h prior to storage at -80°C.

### **Biochemistry analysis**

Analysis of serum, bile, liver and faecal biochemistry were conducted using enzymatic, colorimetric assays on the COBAS Integra 400+ (Roche Diagnostics, Australia) or using gas chromatography mass spectrometry (GS/MS) (see Gas chromatography mass spectrometry analysis). Lipid concentrations were assessed using total cholesterol (CHOL Gen. 2, Roche Diagnostics), high-density lipoprotein cholesterol (HDL-C Gen. 3, Roche Diagnostics), triglycerides (TRIGL, Roche Diagnostics), total bile acids (Total Bile Acids #BI3863, RANDOX, Australia) and phospholipids (Phospholipids C #997-01801, Wako, Japan). Additionally, samples were analysed for total bilirubin (BIL-T Gen. 3, Roche Diagnostics) and albumin (ALB Gen. 2, Roche Diagnostics). All biochemical analysis kits were verified with their appropriate calibrators and quality controls prior to sample analysis.

# Gas chromatography mass spectrometry (GC/MS) analysis

Cholesterol label enrichment and measurement of fractional *de novo* cholesterol synthesis rate, biliary cholesterol concentrations and biliary bile acid species were measured as previously published (Ronda *et al.* 2016). Briefly, cholesterol was extracted from blood spots or bile and derivatized with N,O-Bis (trimethylsilyl) trifluoroacetamide (BSTFA) containing 1% trimethylchlorosilane before analysis with GS/MS (Agilent 7890A and 5975c, respectively; Netherlands). Isotope ratios were determined by selected ion monitoring mode on m/z 458 (M0) to 465 (M7). The fractional rate of cholesterol synthesis was calculated according to mass isotopomer distribution analysis (Ronda *et al.* 2016). Biliary bile acids were extracted and derivatized with

BSTFA-pyridine-trimethylchlorosilane (5:5:0.1) and were quantified using GC/MS. Samples that contained biliary bile acid species below the quantification limit were calculated by dividing the limit of quantification by the square root of two as previously published (Glass & Grey, 2001). The hydrophobicity index of biliary bile acid composition was calculated according to Heuman *et al.* (1989).

### Liver and faecal lipid extraction

Frozen liver tissue (~100 mg) and dried faeces were homogenized using a mortar and pestle and stored at -80°C or RT, respectively, for later lipid extraction. Cholesterol was extracted from homogenized liver and faecal samples by three sequential solvent extractions with isopropyl-alcohol at a 50:1 mg:ml ratio of sample (liver or faeces) to isopropyl-alcohol as previously published (Vidimce et al. 2021). During each extraction, homogenates were vortexed vigorously and sonicated at RT for 10 min prior to centrifugation (43,000 g, 20°C, 10 min). The three supernatant fractions were collected in a separate tube and evaporated using a rotary evaporator (Maxivac, Labogene, Australia) at 35°C. Dry pellets were reconstituted in 250  $\mu$ l of isopropanol and analysed for total cholesterol (see Biochemistry analysis). Bile acids were extracted from homogenized faecal samples using a solvent mixture of 1 M sodium hydroxide and methanol (1:3). Briefly, 1 ml of solvent mixture was added to each 40 mg of homogenized faecal sample and then the sample mixtures were heated for 2 h at 80°C. The samples were then allowed to reach RT before being diluted in H<sub>2</sub>O and centrifuged (43,000 g, 20°C, 10 min). The supernatants were analysed for total bile acid concentration (see Biochemistry analysis).

### **RT-qPCR** array

Liver samples preserved in RNAlater were homogenized in TRIzol reagent (Invitrogen, Australia), and the total RNA was isolated with RNA extraction kits (Qiagen, Australia) as previously published (Ashton et al. 2013). The concentration and purity of RNA was analysed using spectrophotometry (NanoDrop, ThermoFisher Scientific, Australia). First-strand cDNA synthesis kits (Qiagen) were used to synthesize cDNA from total RNA (500 ng) according to the manufacturer's protocol and synthesized cDNA was stored at -20°C for later analysis. Rat Lipoprotein Signalling and Cholesterol Metabolism RT<sup>2</sup> Profiler PCR Arrays (#PARN-080Z, Qiagen) were utilized to measure the expression of 84 key genes using the CFX96 Real-Time PCR Detection System (Bio-Rad, Australia). All data acquisition was performed with CFX Manager 2.0 software (Bio-Rad). Relative mRNA expression was calculated using the 2<sup>( $-\Delta\Delta$ CT)</sup> method to calculate the relative changes of Gunn *versus* control, with normalization of CT values performed against *Rplp1* (ribosomal protein lateral stalk subunit P1) as the most stable reference gene.

### Western blot

Frozen liver samples were homogenized by shearing with 18-23G needles in CelLytic MT Cell Lysis buffer (#C3228) in the presence of protease inhibitor (#P8340) and phosphatase inhibitor (#ab201114, Abcam, USA) as per the manufacturer's protocol. The tissue supernatant was generated by centrifugation (4000 g for 10 min, 4°C) and standardized based on protein concentration using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Australia) as per the manufacturer's protocol. Standardized samples were prepared in Laemmli 2X buffer (#\$3401) at a 1:1 ratio and were heated for 5 min at 95°C or unheated (ABCA1 protein), prior to loading. Proteins  $(10-30 \ \mu g)$  were separated on SDS-PAGE (7.5, 10 or 12%) using TGX FastCast acrylamide kits (#1610171, #1610173 and #1610175, Bio-Rad). After electrophoresis, proteins were transferred onto 0.45  $\mu$ m polyvinylidene fluoride membranes (#IPFL0010, Millipore, Australia) for 1-2 h on ice, in Towbin buffer (25 mм Tris, 192 mм glycine and 20% v/v methanol). Following transfer, membranes were blocked with Odyssey Blocking Buffer (Millenium Science, Australia) and incubated with primary antibodies (HMGCR, #ab174830; SREBP2, #ab30682; B-actin, #ab8226; GAPDH, #sc-32233; CYB5R3, #ab109620; LDLr, #ab30532; CYP7A1, #ab65596; ABCA1, #ab18180) overnight at 4°C with gentle agitation. Finally, membranes were incubated with secondary antibodies (#IRDye 680 or #IRDye 800CW, LI-COR, Australia) for 1 h with gentle agitation at RT and visualized using the Odyssey CLX Infrared Imaging System (LI-COR). Densitometric analysis of target proteins were normalized to GAPDH or  $\beta$ -actin. The linear range of detection was determined for each target and housekeeping (GAPDH and  $\beta$ -actin) proteins prior to analysis. All densitometric analyses were conducted using 5.2 Image Studio Lite (LI-COR).

### **Statistical analysis**

All values are expressed as means  $\pm$  SD or median and interquartile range (IQR). Data were tested for normality and homogeneity of variance with the Kolmogorov–Smirnov and Spearman tests, respectively. Two-way or three-way ANOVA was used to compare the main effects of phenotype (Gunn *vs.* control), sex (male *vs.* female) and age (juvenile vs adult) between groups unless otherwise stated. *Post hoc* comparisons were conducted between phenotype (Gunn *vs.* control rats) of the same age and within the same sex using Fisher's least significant difference test. Statistical analysis was performed in GraphPad PRISM (v9.0) and a P < 0.05 was considered statistically significant.

### Results

# Perturbed serum lipid concentrations in adult female Gunn rats

A total of 36 adult and 30 juvenile animals (Gunn and littermate controls) were assessed for circulating lipid concentrations (see Table 2). Hyperbilirubinaemia was confirmed in adult and juvenile Gunn rats (Main effect: phenotype: P < 0.0001; Table 2). Total cholesterol and HDL-C were significantly reduced in Gunn rats (phenotype: P < 0.0001; Table 2). A significant interaction between phenotype, sex and age (total cholesterol interaction: P = 0.0011; HDL-C interaction: P < 0.0001; Table 2) was reported with *post hoc* analysis revealing that total cholesterol and HDL-C were significantly reduced in adult, but not in juvenile, female Gunn rats (post hoc: P < 0.0001; Table 2). The opposite was observed in male rats, with a significant reduction in total cholesterol (*post hoc*: P = 0.0002) and HDL-C (*post hoc*: P = 0.0060) in juvenile, but not in adult, Gunn rats (Table 2). Phospholipid concentrations were significantly reduced in Gunn rats (phenotype: P = 0.0003; Table 2). Post hoc analysis demonstrated that phospholipids were significantly lower in male juvenile (*post hoc*: P = 0.0121) and female adult Gunn (post hoc: P = 0.0121) rats compared with controls of the same age and sex (Table 2).

# Adult female Gunn rats have reduced body weight and consume fewer calories

Adult rats were housed in metabolic cages for 24 h on four different days to assess daily food, water intake and faecal/urine output (Table 3). Gunn rats had lower body weight than controls (phenotype: P < 0.0001; male Gunn *vs.* controls *post hoc*: P = 0.0129; female Gunn *vs.* control *post hoc*: P < 0.0001; Table 3). *Post hoc* analysis revealed a significantly lower food intake in female Gunn compared with control rats (*post hoc*: P = 0.0147; Table 3).

# Adult female Gunn rats demonstrate elevated fractional cholesterol synthesis

To investigate cholesterol synthesis *in vivo*, acetate pools were enriched with  $[1^{-13}C]$ -acetate supplementation in drinking water. Fractional cholesterol synthesis reflects the *in vivo* rate of cholesterol synthesis determined by the fractional contribution of newly synthesized  $[^{13}C]$ -enriched cholesterol ( $[^{13}C]$ -cholesterol) to the over-

all circulating pool of cholesterol at steady state. There was a significant interaction between phenotype and sex on the rate of fractional cholesterol synthesis (interaction: P = 0.0170; Fig. 1*A*). *Post hoc* analysis demonstrated that female Gunn rats had a significantly greater rate of serum fractional cholesterol synthesis ( $33.8 \pm 3.77 vs. 28.4 \pm 5.73\%$ ; *post hoc*: P = 0.0272), while male Gunn *vs.* control rats showed no difference ( $18.1 \pm 5.98\% vs. 21.3 \pm 4.40\%$ ; *post hoc*: P = 0.210; Fig. 1*A*). Considering that circulating cholesterol levels were lower despite an increased rate of cholesterol content was assessed. However, no difference in hepatic cholesterol content existed (phenotype: P = 0.901; interaction: P = 0.961; Fig. 1*B*).

# Increased biliary and faecal sterol output in adult female Gunn rats

Since hepatic cholesterol content was not different between Gunn and control female rats, it was hypothesized that sterol excretion was enhanced in female Gunn rats, creating a negative sterol balance that is compensated for by increased cholesterol synthesis. Therefore, biliary secretion and faecal lipid excretion were assessed. Bile flow (phenotype: P = 0.0092), biliary cholesterol (phenotype: P = 0.0008) and phospholipid (phenotype: P = 0.0009) secretion were significantly greater in Gunn rats (Fig. 2A-C). Furthermore, there was a significant interaction between sex and phenotype on biliary cholesterol (interaction: P = 0.0411) and phospholipid (interaction: P = 0.0182) secretion (Fig. 2). Post hoc analysis demonstrated that female Gunn rats had significantly greater bile flow (0.67  $\pm$  0.13 vs. 0.47  $\pm$  0.06 ml h<sup>-1</sup> 100 g<sup>-1</sup> body weight; post hoc: P = 0.0035), biliary cholesterol (232 ± 32.7) vs. 141  $\pm$  42.1 nmol h<sup>-1</sup> 100 g<sup>-1</sup> body weight; post hoc: P = 0.0004) and biliary phospholipid secretion  $(1.69 \pm 0.30 \text{ vs. } 0.97 \pm 0.36 \text{ mg h}^{-1} 100 \text{ g}^{-1} \text{ body}$ weight; post hoc: P = 0.0003; Fig. 2A-C) while there was no difference between male Gunn rats and controls. Additionally, female Gunn rats had greater biliary bile acid secretion (7.34  $\pm$  1.75 vs. 5.50  $\pm$  1.67  $\mu$ mol h<sup>-1</sup> 100 g<sup>-1</sup> body weight; *post hoc*: P = 0.0256; Fig. 2). Biliary lipid (cholesterol + phospholipid) secretion relative to bile acid output was elevated in Gunn rats (phenotype:  $P = 0.0018; 0.33 \pm 0.06 vs. 0.24 \pm 0.03$  mol:mol, lipid:bile acids, female Gunn vs. controls; post hoc: P = 0.0073;  $0.31 \pm 0.07$  vs.  $0.25 \pm 0.04$  mol:mol, lipid:bile acids, male Gunn vs. controls; post hoc: P = 0.0476; Fig. 2E).

Daily faecal cholesterol (day 14 phenotype: P = 0.0449; day 18 phenotype: P = 0.0144; Fig. 3*A*-*B*), bile acids (day 14 phenotype: P < 0.0001; day 18 phenotype: P = 0.0002; Fig. 3*C*-*D*) and total sterol (day 14 phenotype: P < 0.0001; day 18 phenotype: P = 0.0003; Fig. 3*E*-*F*) excretion

		nilet	Adı	ult <sup>‡</sup>			Th	ee-way ANOVA	
Variable	Control	Gunn	Control	Gunn	Phenotype <sup>a</sup>	Sex <sup>b</sup>	Age <sup>c</sup>	Interaction	Post hoc
Albumin (g l <sup>-1</sup> )									
Males	30.7 (3.25)	27.1 (7.66)	40.2 (2.87)	43.4 (3.30)	0.559	0.0227	< 0.0001	0.492 <sup>a*b</sup> , 0.672 <sup>a×c</sup> ,	0.154†, 0.211 <sup>‡</sup>
Females	30.5 (1.72)	34.5 (8.86)	44.7 (5.08)	44.1 (3.32)				0.732 <sup>b*c</sup> , <b>0.0352</b> a <b>*b</b> *c	0.194†, 0.809 <sup>‡</sup>
Total bilirubin ( $\mu$ mol l <sup>-1</sup> )									
Males	2.29 (1.53)	72.6 (32.0)	2.29 (1.02)	109 (15.0)	<0.0001	0.0865	0.377	0.0896 <sup>a*b</sup> , 0.369 <sup>a*c</sup> ,	<0.00011, <0.0001 <sup>‡</sup>
Females	2.28 (0.54)	83.9 (34.2)	2.13 (1.54)	64.8 (13.8)				0.0047 <sup>b*c</sup> , 0.0049 <sup>a*b*c</sup>	<0.00011, <0.0001 <sup>‡</sup>
Total cholesterol (mmol l <sup>-1</sup> )									
Males	1.79 (0.51)	1.21 (0.30)	1.56 (0.23)	1.41 (0.15)	<0.0001	0.0005	0.119	0.129 <sup>a*b</sup> , 0.439 <sup>a*c</sup> ,	0.00021, 0.333 <sup>‡</sup>
Females	1.45 (0.32)	1.17 (0.34)	1.56 (0.34)	0.60 (0.12)				0.185 <sup>b*c</sup> , 0.0011 <sup>a*b*c</sup>	0.128†, <0.0001 <sup>‡</sup>
HDL-C (mmol I <sup>-1</sup> )									
Males	1.23 (0.43)	0.89 (0.25)	1.33 (0.22)	1.37 (0.16)	<0.0001	<0.0001	0.191	0.0002 <sup>a*b</sup> , 0.0171 <sup>a*c</sup> ,	0.0060t, 0.772 <sup>‡</sup>
Females	0.99 (0.24)	0.82 (0.32)	1.39 (0.25)	0.20 (0.09)				0.0033 <sup>b*c</sup> , <0.0001 <sup>a*b*c</sup>	0.272†, <0.0001 <sup>‡</sup>
Triglycerides (mmol l <sup>-1</sup> )									
Males	0.93 (0.27)	0.88 (0.32)	1.04 (0.56)	1.19 (0.52)	0.447	0.580	0.457	0.747 <sup>a*b</sup> , 0.721 <sup>a*c</sup> ,	0.811†, 0.508 <sup>‡</sup>
Females	0.89 (0.08)	1.04 (0.55)	0.87 (0.66)	0.98 (0.37)				0.309 <sup>b*c</sup> , 0.605 <sup>a*b*c</sup>	0.579†, 0.633 <sup>‡</sup>
Phospholipids (mg dl <sup>-1</sup> )									
Males	156 (38.0)	120 (21.6)	128 (18.1)	129 (12.9)	0.0003	0.0382	0.0432	0.290 <sup>a*b</sup> , 0.310 <sup>a×c</sup> ,	<b>0.00231</b> , 0.953 <sup>‡</sup>
Females	141 (17.9)	115 (26.7)	130 (29.2)	94.0 (11.9)				0.648 <sup>b*c</sup> , 0.0604 <sup>a*b*c</sup>	0.0725†, <b>0.0034</b> <sup>‡</sup>
Total bile acids ( $\mu$ mol l <sup>-1</sup> )									
Males	100 (72.7)	93.2 (61.3)	16.0 (11.0)	14.2 (4.47)	0.907	0.0205	<0.0001	0.822 <sup>a*b</sup> , 0.317 <sup>a*c</sup> ,	0.766†, 0.947 <sup>‡</sup>
Females	157 (86.0)	134 (69.3)	16.3 (7.35)	41.7 (27.1)				0.190 <sup>b*c</sup> , 0.421 <sup>a*b*c</sup>	0.449†, 0.278 <sup>‡</sup>
Note: Control group represen	its normobiliru	binaemic hete	erozygote litte	ermates. Gunn	group represen	ts hyperbillir	ubinaemic h	iomozygote littermates. Juv	eniles were 3-4 weeks
of age (females: control $n = $	5, Gunn $n = 7$	; males: contro	ol <i>n</i> = 8, Gunr	<i>n =</i> 10). Adu	It rats were 14	weeks of ag	ie (females:	control $n = 9$ , Gunn $n = 10$	); males: control $n = 8$ ,
Gunn $n = 9$ ). Abbreviations: H	DL-C, high-der	nsity lipoprote	in cholesterol.	. Values are rej	presented as me	ans (SD). Th	ree-way AN	OVA was performed with m	ain effects: phenotype
(Gunn or control), sex (male o	or female), and	age (juvenile	or adult). All <i>J</i>	<i>oost ho</i> c analy	ses compared di	fferences be	tween pher	notype of the same age grou	up within the same sex
(† = juvenile; ‡ = adult). Statis	stically significa	ant ( $P < 0.05$ )	P values are h	ighlighted in k	old.				

1896

J Physiol 600.8

	Phenotype		Two-way ANOVA						
Variable	Control	Gunn	Phenotype	Sex	Interaction	Post hoc			
Body weight (g)									
Males	416 (42.7)	382 (27.4)	0.0004	0.0004	0.246	0.0122			
Females	246 (16.2)	191 (12.8)	<0.0001	<0.0001	0.246	<0.0001			
Food intake (kcal day <sup>-1</sup> )									
Males	80.6 (13.1)	79.2 (6.12)	0.0501	0.0001	0 1 4 1	0.720			
Females	61.9 (5.72)	52.5 (5.25)	0.0501	<0.0001	0.141	0.0147			
Water intake (g day <sup>-1</sup> )									
Males	33.3 (8.95)	32.5 (7.13)	0.422	0.246	0.504	0.860			
Females	32.0 (9.04)	28.3 (7.41)	0.423	0.316	0.584	0.329			
Urine output (g day <sup>-1</sup> )									
Males	21.3 (6.59)	21.0 (5.92)	0 540	0.460	0.640	0.925			
Females	20.8 (10.2)	17.7 (7.85)	0.518	0.468	0.610	0.401			
Faecal output (g day <sup>-1</sup> )									
Males	5.20 (0.53)	4.75 (0.81)	0.652	0.0050	0.200	0.234			
Females	4.11 (1.02)	4.33 (0.58)	0.053	0.0059	0.200	0.538			

Note: Control group represents normobilirubinaemic heterozygote littermates. Gunn group represents hyperbilirubinaemic homozygote littermates. Adult rats were 14 weeks of age (females: control n = 9, Gunn n = 10; males: control n = 8, Gunn n = 9). Daily measures are an average of four separate days measured during the study. Values are represented as means (SD). Two-way ANOVA was performed with main effects: phenotype (Gunn or control) and sex (male or female). All *post hoc* analyses compared differences between phenotype within the same sex. Statistically significant (P < 0.05) P values are highlighted in bold.

were significantly greater in Gunn rats than controls, corroborating the idea that increased cholesterol synthesis is a counter-balancing mechanism to increased sterol excretion. Moreover, significant interaction was observed between sex and phenotype for faecal bile acid (day 14 interaction: P < 0.0001; day 18 interaction: P = 0.0005)

and total sterol (day 14 interaction: P < 0.0001; day 18 interaction: P = 0.0025) excretion at days 14 and 18, and at day 14 for faecal cholesterol excretion (interaction: P = 0.0248; Fig. 3). *Post hoc* analysis revealed that faecal bile acid (day 14: P < 0.0001; day 18: P < 0.0001), cholesterol (day 14: P = 0.0028; day 18: P = 0.0113)



### Figure 1. *De novo* fractional cholesterol synthesis and hepatic cholesterol content of adult Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats

*A*, the rate of serum fractional cholesterol synthesis measured as a percentage (%) of newly formed <sup>13</sup>C-cholesterol at steady state. *B*, total cholesterol content per gram of liver tissue. Data are presented as means (SD). Two-way ANOVA was performed with main effects: phenotype (Gunn or control) and sex (male or female). All *post hoc* analyses compared differences between phenotypes within the same sex. Statistically significant (P < 0.05) *P* values are highlighted in bold.

and total sterol excretion (day 14: P < 0.0001; day 18: P < 0.0001) were higher in female Gunn rats than controls, however, no difference existed between male groups (Fig. 3).

### Elevated net intestinal cholesterol flux in female Gunn rats

Faecal cholesterol excretion can be affected by four different mechanisms including: (1) dietary cholesterol intake; (2) biliary cholesterol secretion; (3) transintestinal cholesterol secretion (TICE); and (4) cholesterol reabsorption (Fig. 4). In this study, the diet did not contain

cholesterol, therefore, faecal cholesterol output was only determined by the latter three mechanisms. Since TICE increases while cholesterol reabsorption reduces the rate of faecal cholesterol excretion, their mutually opposing effects can be defined as a net (outward) intestinal cholesterol flux (TICE – cholesterol reabsorption; Fig. 4) (van de Peppel *et al.* 2019). Consequently, net intestinal cholesterol flux can be estimated by subtracting biliary cholesterol secretion from faecal cholesterol excretion. There was no effect of phenotype (P = 0.185) or interaction (P = 0.0931) on the net (outward) intestinal cholesterol flux. However, *post hoc* analysis demonstrated that female Gunn rats had significantly elevated net



# Figure 2. Biliary lipid secretion of adult Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats

*A*, bile flow rate normalized for body weight. *B*–*D*, total cholesterol, phospholipids and bile acids secreted through bile normalized for body weight. *E*, biliary lipid (cholesterol + phospholipid) relative to bile acid secretion (mol:mol). Data are presented as means (SD). Two-way ANOVA was performed with main effects: phenotype (Gunn or control) and sex (male or female). All *post hoc* analyses compared differences between phenotypes within the same sex. Statistically significant (P < 0.05) *P* values are highlighted in bold.

intestinal cholesterol flux compared with controls (P = 0.0427; Fig. 4C).

## Altered bile acid composition in bile of adult female Gunn rats

Considering the enhanced biliary and faecal excretion of total bile acids in female Gunn rats, the biliary bile acid composition was assessed (proportion (%) of individual bile acid species related to total bile acid secretion). Relative secretion of TCA (phenotype: P = 0.0087) was significantly lower while TCDCA (phenotype: P = 0.0226), GCDCA (phenotype: P = 0.0001), TUDCA (phenotype: P = 0.0396) were significantly greater in Gunn rats (Fig. 5). There was also a significant interaction between sex and phenotype on relative secretion of TCA (interaction: P = 0.0015), GCDCA (interaction: P = 0.0005),



# Figure 3. Daily faecal sterol excreted, normalized for body weight of adult Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats

A and B, daily faecal excretion of cholesterol normalized for body weight. C and D, daily faecal excretion of bile acids normalized for body weight. E and F, daily faecal excretion of total sterols (cholesterol + bile acids) normalized for body weight. Data are presented as means (SD). Two-way ANOVA was performed with main effects: phenotype (Gunn or control) and sex (male or female). All *post hoc* analyses compared differences between phenotypes within the same sex. Statistically significant (P < 0.05) P values are highlighted in bold.

TUDCA (interaction: P = 0.0002) and GHDCA (interaction: P = 0.0435; Fig. 5). *Post hoc* analysis demonstrated that the proportion of TCA (*post hoc*: P = 0.0002) was significantly less while CA (*post hoc*: P = 0.0468), GCDCA (*post hoc*: P < 0.0001), TUDCA (*post hoc*: P < 0.0001) and GHDCA (*post hoc*: P = 0.0070) were significantly greater in female Gunn than control rats (Fig. 5). There was a significant interaction between sex and phenotype on the relative secretion of glycine (interaction: P = 0.0327) and taurine (interaction: P = 0.0195) conjugated bile acids (Fig. 6). *Post hoc* analysis showed that relative secretion of glycine (*post hoc*: P = 0.0179) and taurine (*post hoc*: P = 0.0047) conjugated bile acids was greater and reduced, respectively, in female Gunn compared with control rats (Fig. 6).

# Perturbed expression of genes involved in cholesterol metabolism in female Gunn rats

To ascertain whether differences in circulating lipid concentrations and biliary/faecal lipid excretion were



# Figure 4. Net intestinal cholesterol flux of adult Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats

*A*, model describing the four mechanisms (diet, biliary secretion, cholesterol reabsorption and TICE) that affect the rate of faecal cholesterol excretion. *B*, the daily rates of biliary cholesterol secretion, net intestinal cholesterol flux and faecal cholesterol excretion. Since the diet did not contain cholesterol, its contribution was disregarded. The net intestinal cholesterol flux was defined as the overall contribution of TICE and cholesterol reabsorption, and it was estimated by subtracting daily biliary cholesterol secretion from daily faecal cholesterol excretion. *C*, the daily net intestinal cholesterol flux in a graphical format. Data are presented as means (SD). Two-way ANOVA was performed with main effects: phenotype (Gunn or control) and sex (male or female). All *post hoc* analyses compared differences between phenotypes within the same sex. Statistically significant (P < 0.05) *P* values are highlighted in bold.

1901



hoc analyses compared differences between phenotypes within the same sex and only significant (P < 0.05) P values are reported on the figure. [Colour figure can be viewed at wileyonlinelibrary.com]





TCA



Figure 6. Relative contribution of biliary glycine and taurine bile acid species and the hydrophobicity index of adult Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats

*A*, bile acid species are presented as a mole percentage (%) of total bile acids excreted over an hour. *B*, Heuman index of hydrophobicity of the biliary bile acid pool. Two-way ANOVA was performed with main effects: phenotype (Gunn or control) and sex (male or female). All *post hoc* analyses compared differences between phenotypes within the same sex. Statistically significant (P < 0.05) *P* values are highlighted in bold.

0.0105

0.0378

associated with the expression of genes regulating lipid metabolism and transport, RT-qPCR analysis was performed on liver tissue of female adult rats (Fig. 7 and Table 4). The expression of genes regulating several enzymes within the cholesterol synthesis pathway, including *Pmvk* (P = 0.0411) and *Cyb5r3* (P = 0.0288), was significantly decreased (Fig. 7A) while expression of *Hmgcr*, the rate-limiting enzyme of cholesterol synthesis,

0.0288

0.0482

0.0409

0.0274

Figure 7. Hepatic gene expression of female adult Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats A, genes that were significantly different between groups (P < 0.05). B, genes that tended (P < 0.10) to demonstrate differences. Abbreviations: *Pmvk*, phosphomevalonate kinase; *Cyb5r3*, NADH-cytochrome b5 reductase 3; Lrp6, low-density lipoprotein receptor-related protein 6; Colec12, collectin12; Apof, apolipoprotein F; Soat2, sterol O-acyltransferase 2; Ldlr, low-density lipoprotein receptor; Scap, Srebf cleavage activating protein; Tm7sf2, transmembrane 7 subfamily member 2; Trerf1, transcriptional regulating factor 1; Nr1h2, nuclear receptor subfamily 1, group H, member 2; Insig1-2, insulin-induced gene 1-2; Srebf2, sterol regulatory element-binding factor 2. A two-tailed unpaired t test was used for statistical analysis. Fold change data from Table 4 were transformed to log<sub>2</sub> for graphical purposes. Data are presented as medians  $\pm$  range.

was not different between groups (1.04-fold increase in female Gunn rats vs. controls; P = 0.554; Table 4). Furthermore, several genes involved in lipoprotein transport were differentially expressed between groups. Lrp6 (P = 0.0482) and lipoprotein-associated proteins, Colec12 (P = 0.0409) and Apof (P = 0.0274), were significantly reduced, while Ldlr (P = 0.0105) was significantly upregulated in female Gunn rats versus controls (Fig. 7A). Additionally, the gene responsible for cholesterol esterification (Soat2) was significantly increased in female Gunn rats compared with controls (P = 0.0378; Fig. 7A). Finally, genes that tended to differ between groups (P < 0.15) are shown in Fig. 7*B*, while the remaining genes that were not significantly affected are reported in Table 4.

### Altered expression of proteins involved in cholesterol metabolism in female Gunn rats

To determine whether differences in gene expression were related to changes in protein expression, western blot analysis was undertaken on key proteins involved in cholesterol metabolism and lipoprotein transport. Expression of CYB5R3 (P = 0.0276) was reduced while HMGCR expression was non-significantly elevated (P = 0.0794) in female Gunn rats versus controls. No difference in the expression of these proteins was observed in male animals (Fig. 8A-B). CYP7A1 expression, the rate-limiting enzyme of the classical pathway of bile acid synthesis, was significantly greater in male Gunn rats versus controls (P = 0.0170; Fig. 8C). In agreement with gene expression analysis, expression of LDLr was significantly upregulated in female Gunn rats (P = 0.0018) with no difference in male rats (P = 0.582;Fig. 8D). ABCA1 expression was not affected across groups (Fig. 8E). The nuclear form of SREBP2, a master regulator of genes that regulate cholesterol metabolism, was significantly greater in female Gunn rats than in controls (P = 0.0037; Fig. 9). SREBP2 was not measured in male rats because there was no difference in downstream targets, including the fractional rate of cholesterol synthesis and LDLr expression, between groups.

### Discussion

Hyperbilirubinaemia in humans and animal models is associated with reduced circulating cholesterol concentrations. However, an explanation for this relationship remains unknown (Bulmer et al. 2013). Determining the underlying mechanisms causing the hypolipidaemic state is critical to revealing the physiological importance and therapeutic potential of bilirubin/UGT1A1 dysfunction. The main findings of this study included an increased faecal sterol excretion



Α

1.0

0.5

	Gene		
Gene name	abbreviation	Fold change [IQR]	P value
ATP-binding cassette, subfamily A (ABC1), member 1	Abca1	1.02 [0.43]	0.455
ATP-binding cassette, subfamily A (ABC1), member 2	Abca2	1.05 [0.15]	0.310
ATP-binding cassette, subfamily G (WHITE), member 1	Abcg1	0.88 [0.40]	0.548
Aldo-keto reductase family 1, member D1	Akr1d1	1.23 [0.36]	0.363
Angiopoietin-like 3	Angptl3	1.11 [0.26]	0.994
Ankyrin repeat, family A (RFXANK-like), 2	Ankra2	0.91 [0.46]	0.625
Apolipoprotein A-I	Apoa1	0.95 [0.25]	0.231
Apolipoprotein A-II	Apoa2	0.97 [0.06]	0.732
Apolipoprotein A-IV	Apoa4	0.69 [0.17]	0.618
Apolipoprotein B	Apob	0.98 [0.28]	0.294
Apolipoprotein C-I	Apoc1	0.91 [0.13]	0.333
Apolipoprotein C-III	Apoc3	0.85 [0.36]	0.509
Apolipoprotein E	Apoe	0.99 [0.38]	0.548
Apolipoprotein F	Apof	0.80 [0.25]	0.0274
Apolipoprotein L, 2	Apol2	0.57 [0.31]	0.486
Cadherin 13	Cdh13	1.04 [0.51]	0.948
Carboxyl ester lipase	Cel	0.80 [0.63]	0.812
Chymotrypsin-like elastase family, member 3B	Cela3b	0.84 [0.71]	0.850
CCHC-type zinc finger, nucleic acid binding protein	Cnbp	0.82 [0.37]	0.355
Collectin subfamily member 12	Colec12	0.74 [0.23]	0.0409
Chemokine (C-X-C motif) ligand 16	Cxcl16	0.84 [0.19]	0.437
Cytochrome b5 reductase 3	Cyb5r3	0.77 [0.17]	0.0288
Cytochrome P450, family 11, subfamily a, polypeptide 1	Cyp11a1	0.68 [0.83]	0.274
Cytochrome P450, family 39, subfamily a, polypeptide 1	Cyp39a1	1.01 [0.48]	0.884
Cytochrome P450, family 46, subfamily a, polypeptide 1	Cyp46a1	0.90 [0.77]	0.545
Cytochrome P450, family 51	Cyp51	0.79 [0.37]	0.173
Cytochrome P450, family 7, subfamily a, polypeptide 1	Cyp7a1	1.23 [1.69]	0.536
Cytochrome P450, family 7, subfamily b, polypeptide 1	Cyp7b1	0.74 [0.24]	0.216
24-dehydrocholesterol reductase	Dhcr24	1.19 [0.36]	0.382
7-dehydrocholesterol reductase	Dhcr7	1.07 [0.29]	0.655
Emopamil binding protein (sterol isomerase)	Ebp	0.81 [0.31]	0.243
Farnesyl diphosphate farnesyl transferase 1	Fdft1	0.84 [0.44]	0.280
Farnesyl diphosphate synthase	Fdps	0.89 [0.32]	0.164
High-density lipoprotein binding protein	Hdlbp	0.97 [0.17]	0.967
3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Hmgcr	1.04 [1.34]	0.554
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	Hmgcs1	0.86 [0.17]	0.649
Isopentenyl-diphosphate delta isomerase 1	Idi1	0.80 [0.27]	0.912
Interleukin 4	114	0.78 [0.23]	0.613
Insulin-induced gene 1	Insig1	0.66 [0.17]	0.140
Insulin-induced gene 2	Insig2	0.77 [0.29]	0.126
Lecithin cholesterol acyltransferase	Lcat	0.89 [0.30]	0.315
Low-density lipoprotein receptor	Ldlr	1.32 [0.21]	0.0105
Low-density lipoprotein receptor adaptor protein 1	Ldlrap1	0.95 [0.14]	0.737
Leptin	Lep	0.64 [0.76]	0.335
Lipase, hormone sensitive	Lipe	1.14 [0.13]	0.453
Low-density lipoprotein receptor-related protein 10	Lrp10	1.02 [0.04]	0.937
Low-density lipoprotein-related protein 12	Lrp12	1.14 [0.34]	0.739
Low-density lipoprotein receptor-related protein 6	Lrp6	0.73 [0.27]	0.0482
Low-density lipoprotein receptor-related protein associated protein 1	Lrpap1	0.91 [0.32]	0.343
Membrane-bound transcription factor peptidase, site 1	Mbtps1	1.02 [0.25]	0.690
Mevalonate (diphospho) decarboxylase	Mvd	1.13 [0.41]	0.844
Mevalonate kinase	Mvk	1.05 [0.31]	0.880

### Table 4. Hepatic gene expression of female adult Gunn (hyperbilirubinaemic; n = 7) and control (normobilirubinaemic; n = 8) rats. Fold change expressed relative to controls

(Continued)

### Table 4. (Continued)

-	Gene		
Gene name	abbreviation	Fold change [IQR]	P value
Nuclear receptor subfamily 0, group B, member 2	Nr0b2	1.56 [1.00]	0.894
Nuclear receptor subfamily 1, group H, member 2	Nr1h2	0.89 [0.17]	0.0983
Nuclear receptor subfamily 1, group H, member 3	Nr1h3	0.98 [0.17]	0.853
Nuclear receptor subfamily 1, group H, member 4	Nr1h4	1.00 [0.52]	0.663
NAD(P) dependent steroid dehydrogenase-like	Nsdhl	0.77 [0.42]	0.226
Oxidized low-density lipoprotein (lectin-like) receptor 1	Olr1	0.93 [0.27]	0.689
Oxysterol binding protein-like 1A	Osbpl1a	1.00 [0.13]	0.537
Oxysterol binding protein-like 5	Osbpl5	0.88 [0.19]	0.622
Proprotein convertase subtilisin/kexin type 9	Pcsk9	1.10 [0.38]	0.628
Phosphomevalonate kinase	Pmvk	0.66 [0.21]	0.0411
Protein kinase, AMP-activated, alpha 1 catalytic subunit	Prkaa1	0.77 [0.45]	0.361
Protein kinase, AMP-activated, alpha 2 catalytic subunit	Prkaa2	1.07 [0.12]	0.678
Protein kinase, AMP-activated, gamma 2 non-catalytic subunit	Prkag2	0.99 [0.12]	0.756
SREBF chaperone	Scap	0.92 [0.14]	0.0707
Scavenger receptor class F, member 1	Scarf1	0.95 [0.26]	0.696
Sorting nexin 17	Snx17	0.99 [0.19]	0.456
Sterol O-acyltransferase 1	Soat1	0.71 [0.29]	0.163
Sterol O-acyltransferase 2	Soat2	1.14 [0.14]	0.0378
Sortilin-related receptor, LDLR class A repeats-containing	Sorl1	1.06 [0.40]	0.575
Sterol regulatory element-binding transcription factor 1	Srebf1	0.84 [0.66]	0.651
Sterol regulatory element-binding transcription factor 2	Srebf2	0.98 [0.22]	0.141
Stabilin 2	Stab2	0.60 [0.54]	0.372
StAR-related lipid transfer (START) domain containing 3	Stard3	0.92 [0.16]	0.874
Transmembrane 7 superfamily member 2	Tm7sf2	0.81 [0.18]	0.0809
Transcriptional regulating factor 1	Trerf1	0.74 [0.33]	0.0876
Very low-density lipoprotein receptor	Vldlr	1.05 [0.41]	0.973

Note: Control group represents normobilirubinaemic heterozygote littermates. Gunn group represents hyperbilirubinaemic homozygote littermates. Adult rats were 14 weeks of age (females: control n = 8, Gunn n = 7). A two-tailed unpaired t test was used for statistical analysis. Data are presented as median fold changes and interquartile ranges (IQR) compared with controls. Statistically significant (P < 0.05) P values are highlighted in bold.

in female hyperbilirubinaemic Gunn rats which was associated with elevated fractional cholesterol synthesis, greater hepatic LDLr expression and profound hypocholesterolaemia. Surprisingly, the effects of UGT1A1 impairment/hyperbilirubinaemia on sterol metabolism were mostly specific to female animals with only minor effects in male Gunn rats. Increased faecal sterol excretion may explain the negative relationship between bilirubin and circulating cholesterol in hyperbilirubinaemic animals and justifies further investigation in humans with GS.

Adult female Gunn rats demonstrated a >50% reduction in serum cholesterol concentrations compared with controls, largely due to a reduction in HDL-C which is the dominant circulating lipoprotein in rodents (Camus *et al.* 1983). These findings are congruent with previous reports of lower circulating cholesterol in other colonies of female Gunn rats (Boon *et al.* 2012; Wallner *et al.* 2013). In contrast, cholesterol concentrations were not different in adult male rats, which is in opposition to the

results of Wallner et al. (2013), who reported a  $\sim 20\%$ reduction in serum cholesterol in male Gunn rats. This difference in results may be explained by the younger age of the animals studied by Wallner et al. (2013) ( $\sim 8$ vs. 16 weeks of age). Indeed, we found a significant interaction between sex and age in Gunn rats where we observed  $\sim$  30% lower serum cholesterol concentrations in male juvenile rats (3-4 weeks of age) but not in females. A novel finding of this study was that adult female Gunn rats had lower circulating phospholipids. Therefore, changes to circulating lipid concentrations suggest involvement of the liver since it tightly regulates the total body sterol pool (Dietschy & Turley, 2002; Van Der Velde et al. 2010). Moreover, these data broadly suggest that age and sex may play an important role in various aspects of lipid metabolism in hyperbilirubinaemic rats.

Previous studies show that lipid-lowering therapies, including ezetimibe, do not affect the total sterol pool despite reducing circulating cholesterol levels by increasing faecal sterol excretion (Dietschy & Turley, 2002; Jakulj *et al.* 2016; van de Peppel *et al.* 2019). Ezetimibe reduces circulating cholesterol by increasing faecal cholesterol excretion, however, this does not change the sterol pool because of a compensatory increase in cholesterol synthesis (Jakulj *et al.* 2016; van de Peppel *et al.* 2019). Therefore, reduced serum cholesterol concentrations in adult female Gunn rats may be caused indirectly, via a change in sterol excretion. Cholesterol is primarily removed intact or after conversion to bile acids through the gastrointestinal tract as faeces (Van Der Velde *et al.* 2010). Female Gunn rats demonstrated a 33–35% increase in faecal cholesterol output and a more than twofold increase in faecal bile acid excretion compared with controls. Therefore, changes to faecal sterol output must be counterbalanced by dietary intake and/or endogenous synthesis to maintain a constant cholesterol





pool. Considering that the diet consumed by the rats in this study did not contain cholesterol, the sterols lost through faeces must be solely compensated for by endogenous synthesis (Schonewille *et al.* 2016; van de Peppel *et al.* 2019). Consistent with this, fractional cholesterol synthesis was elevated in female Gunn rats counteracting increased sterol excretion to maintain cholesterol balance.

Although this study clearly describes the functional impact of hyperbilirubinaemia/UGT1A1 dysfunction on sterol excretion, the mechanism explaining this effect remains to be elucidated. Nevertheless, increased bile acid excretion can only be attributed to one of three mechanisms including: (1) increased biliary bile acid secretion; (2) decreased intestinal bile acid reabsorption; or (3) a combination of 1 and 2 (de Boer et al. 2018). Even though biliary bile acid secretion was elevated by 33% in adult female Gunn rats this cannot account for the more than twofold higher faecal bile acid excretion compared with female control rats. Therefore, it can be assumed that the greater faecal bile acid excretion in Gunn rats is primarily caused by reduced intestinal reabsorption. Studies investigating the impact of disrupted intestinal bile acid reabsorption on sterol metabolism report similar findings observed in female Gunn rats. For instance, ABST<sup>-/-</sup> mice with impaired intestinal bile acid reabsorption demonstrate a more than twofold increase in faecal sterol excretion with an increase in *in vivo* cholesterol synthesis and greater gene expression of Cyp7a1, the rate-limiting enzyme of bile acid synthesis (van de Peppel et al. 2019). Increased bile acid synthesis is a physiological response to offset the depleted bile acid pool in conditions of elevated bile acid excretion (van de Peppel et al. 2019). Similar results are found in animal studies of complete bile diversion (Smit et al. 1990) and in animals/humans treated with bile acid-sequestering medication that enhance faecal bile acid loss (Einarsson *et al.* 1991). Given that bile acid excretion equals bile acid synthesis at steady state (Chiang, 2013), adult female Gunn rats must experience increased bile acid synthesis. This conclusion is partly supported by a non-significant (P = 0.245) 27% greater hepatic CYP7A1 protein expression in adult female Gunn rats compared with controls. Nevertheless, future investigations are required to confirm that bile acid reabsorption is reduced in female Gunn rats and that this is the primary cause of increased faecal bile acid excretion.

Intriguingly, adult female Gunn rats also show greater biliary cholesterol secretion. It is tempting to speculate that increased cholesterol synthesis and/or increased HDL-C uptake are involved in this observation (Dikkers & Tietge, 2010). Biliary cholesterol can predominantly originate from HDL-C and the rate of hepatic HDL-C uptake could impact the rate of biliary cholesterol secretion (Dikkers & Tietge, 2010). The profoundly reduced serum HDL-C concentrations in female Gunn rats may be related to reduced HDL production, increased clearance, or both. It seems less likely that female Gunn rats had reduced HDL-C production because hepatic ABCA1 hepatic protein and Apoa1 gene (Table 4) expression were unchanged. Rather, increased hepatic HDL-C uptake could be related to the increased biliary cholesterol secretion in female Gunn rats (Dikkers & Tietge, 2010). Alternatively, biliary cholesterol secretion may have been increased in female Gunn rats due to increased coupling of lipids to bile acid secretion due to reduced biliary concentration of bilirubin conjugates (Bulmer et al. 2013). Conjugated bilirubin and other organic anions dissociate biliary lipid secretion from bile acids and cause a reduction in overall biliary output of cholesterol and phospholipids (Verkade, 2000). However,



Figure 9. Protein expression analysis using western blot for nuclear form of SREBP2 (n-SREBP2) in livers from adult female Gunn (hyperbilirubinaemic) and control (normobilirubinaemic) rats

*A*, SREBP2 expression normalized to GAPDH expression. *B*, an example cropped image that represents a single western blot run. Abbreviations: SREBP2, sterol regulatory element-binding protein 2. Data are presented as means (SD). Statistical analyses were conducted using unpaired *t* tests. Statistically significant (P < 0.05) *P* values are highlighted in bold.

J Physiol 600.8

these studies commonly infused supra-physiological concentrations of organic anions. Thus, it is unknown whether increased coupling occurs at physiological or sub-physiological levels of organic anions in bile. The current study presents the first evidence of increased coupling of biliary lipids to bile acid secretion in Gunn rats that secrete substantially lower amounts of bilirubin conjugates in bile. Adult Gunn rats demonstrated greater relative secretion of biliary lipids to bile acids in part explaining the higher biliary cholesterol and phospholipid secretion in females.

Hepatic gene and protein expression was assessed to explore the impact of increased faecal sterol excretion on cholesterol metabolism and hypocholesterolaemia in female Gunn rats. Hepatic LDLr expression was elevated in female Gunn rats; a finding which is compatible with hypocholesterolaemia and increased cholesterol uptake by the liver (Daniels et al. 2009). Furthermore, female Gunn rats demonstrated elevated protein expression of the nuclear form of SREBP2, which is a master regulator of cholesterol metabolism that acts as a sterol-sensing transcription factor (Eberlé et al. 2004). During decreased intracellular cholesterol levels, endoplasmic reticulum-bound SREBP2 is cleaved from the SREBP2-SCAP-INSIG complex and translocates to the nucleus where it transactivates genes involved in cholesterol synthesis and transport (Eberlé et al. 2004). SREBP2 positively regulates expression of Hmgcr, Ldlr, Pmvk, Hmgcs, Abcg5 and Abcg8 (Horton et al. 2003). Therefore, increased Ldlr expression in female Gunn rats is consistent with greater expression of the nuclear form of SREBP2. However, no significant change in Hmgcr or Hmgcs gene expression occurred, while Pmvk gene expression was significantly decreased (Fig. 7). Although expression of Abcg5 and Abcg8 was not measured, female Gunn rats demonstrated greater biliary cholesterol secretion, indicating that the expression of these genes may be increased because they mediate the export of hepatic sterols into the bile canaliculus (Boyer, 2013).

Gene expression data of selected targets was validated using protein expression. Hepatic HMGCR protein expression tended to increase by  $\sim 40\%$  (P = 0.0794) in female Gunn rats, consistent with increased SREBP2 protein expression and cholesterol synthesis in the same animals (Van Der Wulp et al. 2013). Therefore, greater (rate-limiting) HMGCR expression potentially explains the elevated rate of cholesterol synthesis in female Gunn rats (DeBose-Boyd, 2008). Surprisingly, gene expression of Hmgcr was not elevated, suggesting that increased protein expression may occur due to reduced post-translational degradation of HMGCR in female Gunn rats mediated by reduced gene expression of *Insig1* and *Insig2* (*P* < 0.15; Fig. 7*B*) (DeBose-Boyd, 2008; Van Der Wulp et al. 2013). Taken together, these results suggest that female Gunn rats have increased hepatic uptake of circulating cholesterol and elevated cholesterol synthesis, and this could be mediated through enhanced nuclear expression of SREBP2. However, to confirm this, future studies need to investigate the expression of other important cholesterol uptake receptors such as scavenger receptor class B type 1 and transcription factors such as SREBP1a. Nevertheless, this pattern of gene/protein regulation is a typical physiological response to reduced hepatic cholesterol content that aims to restore intracellular cholesterol as reported with lipid-lowering therapies (Schonewille *et al.* 2016).

Hepatic cholesterol concentrations are also affected by the rate of intestinal cholesterol absorption. Increased faecal cholesterol excretion in adult female Gunn rats suggests decreased intestinal reabsorption of cholesterol (Jakulj et al. 2010). Interestingly, bile acids are vital for efficient cholesterol absorption and their effectiveness varies depending on their physiochemical properties (de Boer et al. 2018). Wang et al. (2003) demonstrated that the hydrophobicity index of the biliary bile acid composition (Heuman index) was strongly and positively related to intestinal cholesterol absorption (Heuman et al. 1989; Wang et al. 2003). In comparison to hydrophilic bile acids (e.g.  $\alpha/\beta$ -MCA species), hydrophobic species such as CA and TCA are potent inducers of cholesterol absorption (Wang et al. 2003). A profoundly lower proportion of TCA was measured in the bile of female Gunn rats (minor elevation in MCA species). The reason for the difference in the proportions of bile acid species in female Gunn rats remains unknown; however, the overall hydrophobicity index did not change. These data suggest that the difference in biliary bile acid composition in female Gunn rats was unlikely to affect cholesterol reabsorption.

Intestinal cholesterol reabsorption is also affected by the rate of bile acid reabsorption. In adult female Gunn rats, a profound increase in faecal bile acid excretion occurred, strongly suggesting reduced intestinal reabsorption of bile acids. ASBT-/- mice with reduced intestinal bile acid reabsorption also demonstrate a substantial decrease in cholesterol reabsorption underpinning the co-dependence of these two pathways (van de Peppel et al. 2019). Indeed, female Gunn rats had elevated net intestinal cholesterol flux which can only be a result of reduced intestinal cholesterol reabsorption and/or by increased TICE (van de Peppel et al. 2019). Consequently, it is tempting to speculate that cholesterol reabsorption is reduced in female Gunn rats. However, it is not possible to separate the individual contributions of the two mechanisms. Collectively, the findings of this study support a conclusion that perturbation in cholesterol balance in female Gunn rats is caused by increased excretion of bile acids and to a lesser extent of cholesterol. The resulting negative intestinal sterol balance is compensated for by elevated cholesterol synthesis.

Hepatic UGT1A1 is an important enzyme for competes  $17\beta$ -oestradiol excretion. UCB with  $17\beta$ -oestradiol for conjugation by UGT1A1 (Zhou et al. 2011; Sambasivarao, 2013); therefore, UGT1A1 dysfunction in Gunn rats possibly reduces  $17\beta$ -oestradiol excretion. Although circulating hormone concentrations were not measured in this study, it is plausible that female Gunn rats contain elevated levels of  $17\beta$ -oestradiol. The impact of oestrogen on lipid metabolism is well established in both humans and animals (Palmisano et al. 2017). Ovariectomized animals with very low oestrogen levels are heavier and have substantially higher serum cholesterol concentrations which are reversed by treatment with oestrogen, establishing a causal relationship of oestrogen with respect to lipid metabolism (Zhu et al. 2013). Interestingly, reduced circulating cholesterol concentrations following oestrogen treatment in rats are associated with increased LDLr expression suggesting that oestrogen induces hepatic cholesterol uptake (Koopen et al. 1999). Collectively, elevated oestrogen concentrations may potentially explain the hypocholesterolaemia and enhanced LDLr expression in female Gunn rats and this requires further investigation.

Considering that male animals are unlikely to experience the confounding effects of oestrogen metabolism, the effect of UGT1A1 inhibition and hyperbilirubinaemia, should be clearer in these animals. Under these conditions, effects on lipid metabolism appeared to be milder in male Gunn rats. Although adult male Gunn rats demonstrated significantly lower body mass there was no change in serum cholesterol or any measures of sterol metabolism. Conversely, lower serum cholesterol was found in juvenile male Gunn rats, indicating that age plays an important factor in sterol metabolism in Gunn rats. In juvenile male Gunn rats, different mechanisms from those in females must be responsible for reduced cholesterol concentrations. These potentially relate to bilirubin more specifically. Bilirubin is an endogenous ligand for the AhR and PPAR $\alpha$ , which are ligand-activated transcription factors that regulate lipid metabolism (Phelan et al. 1998; Stec et al. 2016). In our previous study we found that downstream targets of PPAR $\alpha$  were specifically upregulated in adult male, but not in female, Gunn rats (Vidimce et al. 2021). This suggests that bilirubin regulates lipid metabolism through PPAR $\alpha$  in male Gunn rats, but an alternative mechanism must be responsible for the changes observed in females. However, unlike studies with hyperbilirubinaemic mice that show PPAR $\alpha$ -mediated decreases in adiposity (Hinds et al. 2017), minimal changes to fat metabolism occur in male Gunn rats (Vidimce et al. 2021).

Alternatively, bilirubin could modulate lipid metabolism by binding to AhR. Ligand activation of AhR causes repression of several genes involved in cholesterol metabolism such as *Hmgcr*, *Hmgcs* and *Pmvk* (Tanos *et al.* 2012). It is yet to be demonstrated whether AhR is activated *in vivo* in hyperbilirubinaemic animal models, although preliminary evidence shows that downstream genes of AhR are upregulated in juvenile but not in adult Gunn rats (Kapitulnik & Gonzalez, 1993). The mechanisms responsible for the changes to lipid metabolism in Gunn rats remain unknown. However, they could include bilirubin agonism of PPAR $\alpha$  and AhR, and/or elevated oestrogen concentrations due to UGT1A1 impairment. Future studies are required to explore the importance of these receptors and of oestrogen in the regulation of lipid metabolism in hyperbilirubinaemic rats.

# Limitations

In rats, HDL constitutes the greatest lipoprotein fraction involved in plasma cholesterol transport, as opposed to humans where the LDL particle is generally more abundant (Van Der Wulp *et al.* 2013). As such, future studies should evaluate the effects of hyperbilirubinaemia in genetic knockout models that more closely resemble human cholesterol transport such as the LDL knockout mouse model. Nonetheless, increased LDLr expression in female Gunn rats provides preliminary evidence that suggests greater LDL-mediated cholesterol clearance in hyperbilirubinaemia.

# Conclusion

Individuals with elevated circulating concentrations of bilirubin have reduced circulating cholesterol and are protected from CVD. However, very little is understood regarding how these affects are mediated in vivo (Bulmer et al. 2013). This is the first study to demonstrate substantially elevated sterol excretion in female hyperbilirubinaemic Gunn rats. The increased sterol excretion creates a negative intestinal sterol balance that is compensated for by elevated cholesterol synthesis and increased hepatic LDLr expression. Elevated LDLr expression is likely responsible for depleting the circulating cholesterol pool causing hypocholesterolaemia in female Gunn rats. Surprisingly there was significant sexual dimorphism in the changes to sterol metabolism suggesting perturbation of sex hormone metabolism in female UGT1A1-deficient Gunn rats, and therefore, it remains unclear as to whether bilirubin, per se, is responsible for these reported hypolipidaemic effects. These data collectively support additional mechanisms to explain cardiovascular disease protection, which could be extrapolated to humans with impaired UGT1A1 function (including GS).

# References

Ashton KJ, Tupicoff A, Williams-Pritchard G, Kiessling CJ, See Hoe LE, Headrick JP & Peart JN (2013). Unique transcriptional profile of sustained ligand-activated preconditioning in pre- and post-ischemic myocardium ed. Kukreja R. *PLoS One* **8**, e72278.

de Boer JF, Kuipers F & Groen AK (2018). Cholesterol transport revisited: a new turbo mechanism to drive cholesterol excretion. *Trends Endocrinol Metab* **29**, 123–133.

Boon AC, Hawkins CL, Bisht K, Coombes JS, Bakrania B, Wagner KH & Bulmer AC (2012). Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. *Free Radic Biol Med* **52**, 2120–2127.

Boyer JL (2013). Bile formation and secretion. *Compr Physiol* **3**, 1035–1078.

Bulmer AC, Bakrania B, Du Toit EF, Boon AC, Clark PJ, Powell LW, Wagner KH & Headrick JP (2018). Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea. *Am J Physiol - Hear Circ Physiol* **315**, H429–H447.

Bulmer AC, Blanchfield JT, Toth I, Fassett RG & Coombes JS (2008). Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. *Atherosclerosis* **199**, 390–396.

Bulmer AC, Verkade HJ & Wagner KH (2013). Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. *Prog Lipid Res* **52**, 193–205.

Camus MC, Chapman MJ, Forgez P & Laplaud PM (1983). Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus. *J Lipid Res* **24**, 1210–1228.

Chiang JYL (2013). Bile acid metabolism and signaling. In *Comprehensive Physiology*, pp. 1191–1212. Wiley.

Daniels TF, Killinger KM, Michal JJ, Wright RW & Jiang Z (2009). Lipoproteins, cholesterol homeostasis and cardiac health. *Int J Biol Sci* **5**, 474–488.

DeBose-Boyd RA (2008). Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. *Cell Res* **18**, 609–621.

Dietschy JM & Turley SD (2002). Control of cholesterol turnover in the mouse. *J Biol Chem* 277, 3801–3804.

Dikkers A & Tietge UJF (2010). Biliary cholesterol secretion: more than a simple ABC. *World J Gastroenterol* **16**, 5936–5945.

Eberlé D, Hegarty B, Bossard P, Ferré P & Foufelle F (2004). SREBP transcription factors: master regulators of lipid homeostasis. *Biochimie* **86**, 839–848.

Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D & Angelin B (1991). Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. *Eur J Clin Pharmacol* **40**, S53–S58.

Glass DC & Gray CN (2001). Estimating mean exposures from censored data: exposure to benzene in the Australian petroleum industry. *Ann Occup Hyg* **45**, 275–282.

Grundy D (2015). Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology. *J Physiol* **593**, 2547–2549. Heuman DM, Hylemon PB & Vlahcevic ZR (1989). Regulation of bile acid synthesis. III. Correlation between biliary bile salt hydrophobicity index and the activities of enzymes regulating cholesterol and bile acid synthesis in the rat. *J Lipid Res* **30**, 1161–1171.

Hinds TD, Hosick PA, Chen S, Tukey RH, Hankins MW, Nestor-Kalinoski A & Stec DE (2017). Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPAR $\alpha$ . *Am J Physiol - Endocrinol Metab* **312**, E244–E252.

Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM & Williams RR (1996). Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. *Arterioscler Thromb Vasc Biol* **16**, 250 LP–255.

Horsfall LJ, Nazareth I, Pereira SP & Petersen I (2013). Gilbert's syndrome and the risk of death: a population-based cohort study. *J Gastroenterol Hepatol* **28**, 1643–1647.

Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS & Goldstein JL (2003). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. *Proc Natl Acad Sci U S A* **100**, 12027–12032.

Insull W (2009). The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. *Am J Med* **122**, S3–S14.

Jakulj L, van Dijk TH, de Boer JF, Kootte RS, Schonewille M, Paalvast Y, Boer T, Bloks VW, Boverhof R, Nieuwdorp M, Beuers UHW, Stroes ESG & Groen AK (2016). Transintestinal cholesterol transport is active in mice and humans and controls ezetimibe-induced fecal neutral sterol excretion. *Cell Metab* **24**, 783–794.

Jakulj L, Vissers MN, van Roomen CP, van der Veen JN, Vrins CLJ, Kunne C, Stellaard F, Kastelein JJP & Groen AK (2010). Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice. *FEBS Lett* **584**, 3625–3628.

Kapitulnik J & Gonzalez JF (1993). Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. *Mol Pharmacol* **43**, 722–725.

Koopen NR, Post SM, Wolters H, Havinga R, Stellaard F, Boverhof R, Kuipers F & Princen HMG (1999). Differential effects of  $17\alpha$ -ethinylestradiol on the neutral and acidic pathways of bile salt synthesis in the rat. *J Lipid Res* **40**, 100–108.

Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S & Kronenberg F (2006). Association between the UGT1A1\*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. *Circulation* **114**, 1476–1481.

Neuzil J & Stocker R (1994). Free and albumin-bound bilirubin are efficient co-antioxidants for α-Tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. *J Biol Chem* **269**, 16712–16719.

Novotný L & Vítek L (2003). Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. *Exp Biol Med* **228**, 568–571. Palmisano BT, Zhu L & Stafford JM (2017). Role of estrogens in the regulation of liver lipid metabolism. *Adv Exp Med Biol* **1043**, 227–256.

van de Peppel IP, Bertolini A, van Dijk TH, Groen AK, Jonker JW & Verkade HJ (2019). Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice. *J Lipid Res* **60**, 1562–1572.

Phelan D, Winter GM, Rogers WJ, Lam JC & Denison MS (1998). Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. *Arch Biochem Biophys* **357**, 155–163.

Ronda OAHO, van Dijk TH, Verkade HJ & Groen AK (2016). Measurement of intestinal and peripheral cholesterol fluxes by a dual-tracer balance method. *Curr Protoc Mouse Biol* **6**, 408–434.

Sambasivarao SV (2013). Glucuronidation of the steroid enantiomers ent- $17\beta$ -estradiol ent-androsterone and ent-etiocholanolone by the human UDP-glucuronosyltransferases. *J Steroid Biochem Mol Biol* **18**, 1199–1216.

Schonewille M, De Boer JF, Mele L, Wolters H, Bloks VW, Wolters JC, Kuivenhoven JA, Tietge UJF, Brufau G & Groen AK (2016). Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. *J Lipid Res* **57**, 1455–1464.

Seyed Khoei N, Grindel A, Wallner M, Mölzer C, Doberer D, Marculescu R, Bulmer A & Wagner KH (2018). Mild hyperbilirubinaemia as an endogenous mitigator of overweight and obesity: implications for improved metabolic health. *Atherosclerosis* **269**, 306–311.

Smit MJ, Temmerman AM, Havinga R, Kuipers F & Vonk RJ (1990). Short- and long-term effects of biliary drainage on hepatic cholesterol metabolism in the rat. *Biochem J* **269**, 781–788.

Stec DE, John K, Trabbic CJ, Luniwal A, Hankins MW, Baum J & Hinds TD (2016). Bilirubin binding to PPARα inhibits lipid accumulation. *PLoS One* 11, e0153427.

Stocker R, Yamamoto Y, McDonagh AF, Glazer AN & Ames BN (1987). Bilirubin is an antioxidant of possible physiological importance. *Science* 235, 1043–1046.

Tabas I, García-Cardeña G & Owens GK (2015). Recent insights into the cellular biology of atherosclerosis. *J Cell Biol* **209**, 13–22.

Tanos R, Patel RD, Murray IA, Smith PB, Patterson AD & Perdew GH (2012). Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent manner. *Hepatology* 55, 1994–2004.

Van Der Velde AE, Brufau G & Groen AK (2010). Transintestinal cholesterol efflux. *Curr Opin Lipidol* 21, 167–171.

Verkade HJ (2000). Inhibition of biliary phospholipid and cholesterol secretion by organic anions affects bile canalicular membrane composition and fluidity. *J Gastroenterol* **35**, 481–485.

Vidimce J, Pillay J, Shrestha N, Dong L, Neuzil J, Wagner K-H, Holland OJ & Bulmer AC (2021). Mitochondrial function, fatty acid metabolism, and body composition in the hyperbilirubinemic gunn rat. *Front Pharmacol* **12**, 1–18. Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC & Wagner KH (2013). Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. *Clin Sci* **125**, 257–264.

Wang DQH, Tazuma S, Cohen DE & Carey MC (2003). Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. *Am J Physiol - Gastrointest Liver Physiol* 285, G494-G502.

Van Der Wulp MYM, Verkade HJ & Groen AK (2013). Regulation of cholesterol homeostasis. *Mol Cell Endocrinol* **368**, 1–16.

Yoon M (2009). The role of PPAR $\alpha$  in lipid metabolism and obesity: focusing on the effects of estrogen on PPAR $\alpha$  actions. *Pharmacol Res* **60**, 151–159.

Zhou J, Tracy TS & Remmel RP (2011). Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the presence of model UDP-Glucuronosyltransferase 1A1 substrates/inhibitors. *Drug Metab Dispos* **39**, 322–329.

Zhu L, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP & Stafford JM (2013). Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. *Diabetes* **62**, 424–434.

# **Additional information**

# Data availability statement

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation, to any qualified researcher upon request.

# **Competing interests**

The authors declare that the research was conducted in the absence of any conflict of interest.

# **Author contributions**

J.V. designed and performed the research, analysed the data and wrote the manuscript. A.B. assisted with method development, study design and terminal procedures. A.B. also had a primary role in supervision and revision of the manuscript. J.P. assisted with all animal work and biochemistry analysis, and conducted bile duct cannulations, measurement of CYP7A1 and hepatic lipid concentrations. O.R., H.V. and T.D. assisted with planning the study design and method development, and measured the rate of cholesterol synthesis, biliary cholesterol concentrations and biliary bile acid species. A.-C.B. and K.A. conducted PCR analysis. E.P. assisted with the biochemical analysis. J.P., O.R., H.V., T.D., E.P. and K.W. contributed to the interpretation of the results. All authors contributed to the critical revision of the manuscript. All authors approved the final version and submission of this manuscript. Open access publishing facilitated by Griffith University, as part of the Wiley – Griffith University agreement via the Council of Australian University Librarians.

### Funding

Funding for this research was provided by the School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia. This research was also supported by a research grant provided by the Der Wissenschaftsfonds, Austria (FWF, Grant ID: P29608).

### **Keywords**

bile acid metabolism, cholesterol metabolism, Gilbert's syndrome, LDL receptor, lipid, SREBP, UGT1A1, unconjugated bilirubin

## **Supporting information**

Additional supporting information can be found online in the Supporting Information section at the end of the HTML view of the article. Supporting information files available:

### Statistical Summary Document Peer Review History